<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485990</url>
  </required_header>
  <id_info>
    <org_study_id>J15113</org_study_id>
    <nct_id>NCT02485990</nct_id>
  </id_info>
  <brief_title>Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)</brief_title>
  <official_title>An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be looking at what dose of tremelimumab and olaparib is safe and effective in
      patients with persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal
      Carcinoma).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by the rate of AEs, serious AEs, deaths and laboratory abnormalities (e.g. Grade 3 or higher per CTCAE v4)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A: Tremelimumab Alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 patients will receive tremelimumab alone at 10 mg/kg IV every 4 weeks for 7 doses then every 12 weeks until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B1: DESE Tremelimumab and Olaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 patients will receive tremelimumab (3 or 10 mg/kg IV) every 4 weeks for 7 doses then every 12 weeks and olaparib (150 or 300 mg orally twice a day) until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B2: Tremelimumab and Olaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 patients will receive tremelimumab (every 4 weeks for 7 doses then every 12 weeks) and olaparib (daily) until disease progression. Dose of tremelimumab and olaparib will be determined during the DESE (Arm B1).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <arm_group_label>Arm A: Tremelimumab Alone</arm_group_label>
    <arm_group_label>Arm B1: DESE Tremelimumab and Olaparib</arm_group_label>
    <arm_group_label>Arm B2: Tremelimumab and Olaparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <arm_group_label>Arm B1: DESE Tremelimumab and Olaparib</arm_group_label>
    <arm_group_label>Arm B2: Tremelimumab and Olaparib</arm_group_label>
    <other_name>LYNPARZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent form

          2. Age â‰¥ 18 years

          3. Recurrent or persistent EOC (epithelial ovarian, fallopian tube or primary peritoneal
             carcinoma)

          4. Have archival tissue or willingness to undergo a tumor biopsy

          5. Have measurable disease

          6. Have had one prior taxane-platinum-based chemotherapeutic regimen

          7. Have had a treatment-free interval following platinum-based therapy of less than 12
             months, have progressed during platinum-based therapy, or had persistent disease after
             a platinum-based regimen

          8. Have received hormonal therapy

          9. ECOG Performance Status of 0 to 1

         10. Ability to take oral medications

         11. HIV, HTLV-1, HBV, and HCV negative

         12. Adequate organ and bone marrow function as defined by study-specified laboratory tests

         13. Normal blood coagulation parameters

         14. Life expectancy greater than 16 weeks

         15. Must use acceptable form of birth control through the study and for 28 days after
             final dose of study drug

         16. Willing and able to comply with study procedures

        Exclusion Criteria:

          1. Prior therapy with an anti-CTLA-4 antibody or PARP inhibitor

          2. Active infection requiring antibiotics

          3. Active autoimmune disease

          4. Active and uncontrolled intercurrent illness

          5. History of other cancers within the past 5 years

          6. Systemically active steroid use

          7. Receiving systemic chemotherapy or radiotherapy within 4 weeks prior to the first dose
             of study drug

          8. Use of ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin,
             clarithromycin and nelfinavir

          9. Requirement for chronic parenteral hydration/nutrition

         10. Vaccination with live attenuated vaccine within 1 month prior to first dose of study
             drug

         11. Patients with untreated brain metastases, treated brain metastases that are not
             stable, leptomeningeal disease, or seizures uncontrolled with standard medical therapy

         12. Patients with myelodysplastic syndrome/acute myeloid leukaemia

         13. History of diverticulitis

         14. History of bleeding disorder or diathesis.

         15. Serious or nonhealing wound, ulcer, bone fracture, or osteonecrosis of the jaw

         16. Major surgical procedure within 28 days of study enrollment, or anticipated while on
             study.

         17. Pregnant or breast feeding woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leisha Emens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maureen Berg, RN</last_name>
    <phone>443-287-6602</phone>
    <email>mberg1@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Berg, RN</last_name>
      <phone>443-287-6602</phone>
      <email>mberg1@jhmi.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>June 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fallopian Tube</keyword>
  <keyword>Epithelial Ovarian</keyword>
  <keyword>EOC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

